

NXG All4Equality



NAV: USD 81.65

ISIN: CH1145151747

June 2022

Investment objective

The NXG All4Equality Strategy focuses on selecting shares of global companies that are among the leaders on the implementation of policies regarding gender equality. The strategy aims at promoting objective 5 of UN's Sustainable Development Goals: Achieve gender equality and empower all women and girls.

Key features

- Concentrated portfolio of around 30 companies
- Gender equality played through best-in-class companies
- Actively managed portfolio

AMC data

| | |
|-------------------------|----------------------------|
| Quote | 81.65 |
| Share class currency | USD |
| AUM (USD Mn) | 4.9 |
| Advisor | NextGen Wealth Managers SA |
| Calculation Agent | Bank Vontobel AG, Zurich |
| ISIN | CH1145151747 |
| Valor | 114515174 |
| Benchmark | MSCI World TR Index (MSCI) |
| Issue date | 13.12.2021 |
| Management fees | 0.65% |
| Administration fees | 0.30% |
| Performance fees | - |
| Quotation | Daily |
| Subscription/redemption | Daily (cut-off: 15:00 CET) |
| Minimum investment | 1 Certificate |
| Registration | Switzerland |
| Domicile | Switzerland |
| Dividend distribution | Capitalized |


Monthly comment

Markets have experienced the worst first half of the year for equities in over 50 years. This environment of monetary tightening after a decade of accommodative monetary policies led to strongly negative performance in global stock markets. The portfolio dropped by 9.7% in June compared to 8.7% for the MSCI World, standing at -20.8% against -20.5% for the benchmark since the beginning of the year. Annualized volatilities stand at 19.5% and 20.9% respectively. The main reason for the weak global equity performance has been concerns that persistently high inflation will lead to aggressive central bank tightening and undermine consumer spending.

Over the month, the performance gap between the portfolio and its benchmark was mainly due to the selection effect, while the allocation and currency effects remained neutral. The allocation of consumer staples was the main positive driver, whereas the selection of information technology and materials stocks were the main detractors during the month. Our underweight in materials also dampened the performance. Top contributors were Colgate-Palmolive (+1.69%), Estee Lauder (+0.01%) and AstraZeneca (+3.31%), while Anglo American (-24.4%), Dow (-24.1%) and Aker (-15.7%) were the main detractors.

We started the month with 3% of cash, as a liquidity buffer to seize possible investment opportunities, to finish the month fully invested and increased our allocation of consumer staples and materials.

Performance graph



Performance table (%)

| | | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|------|------|------|------|-----|------|-----|------|-----|-----|-----|-----|-----|-----|-------|
| 2022 | PTF | -3.5 | -3.8 | 1.4 | -7.2 | 0.5 | -9.7 | | | | | | | -20.8 |
| | MSCI | -5.3 | -2.5 | 2.7 | -8.3 | 0.1 | -8.7 | | | | | | | -20.5 |
| 2021 | PTF | | | | | | | | | | | | 3.1 | 3.1 |
| | MSCI | | | | | | | | | | | | 2.3 | 2.3 |

Statistics

| | PTF | MSCI | PTF | MSCI |
|-----------------------------|-------|-------|---------------------------|-----------|
| Perf. since inception (%) | -18.3 | -18.7 | Dividend yield % | 3.0 2.2 |
| Standard deviation p.a. (%) | 19.5 | 20.9 | P/E fwd 12m | 13.0 15.7 |
| Max drawdown (%) | -22.9 | -23.4 | P/CF fwd 12m | 8.6 11.0 |
| Sharpe ratio | -1.5 | -0.9 | P/B fwd 12m | 2.4 2.6 |
| Information ratio | 0.16 | | Debt/equity | 135 135 |
| Beta (ex-post) | 0.77 | | Current ratio | 1.2 1.2 |
| Correlation | 0.91 | | Avg. market cap. (USD Bn) | 140 377 |
| Number of positions | 34 | 1'542 | Avg. ESG rating (MSCI) | AA AA |


Top positions

| Name | Sector | Country | Weight |
|------------------------|------------------|---------------|--------|
| 1 Coca-Cola Co/The | Consumer Staples | United States | 3.9% |
| 2 Ventas Inc | Real Estate | United States | 3.8% |
| 3 Merck & Co Inc | Health Care | United States | 3.7% |
| 4 Novartis AG | Health Care | Switzerland | 3.6% |
| 5 AstraZeneca PLC | Health Care | Britain | 3.5% |
| 6 Colgate-Palmolive Co | Consumer Staples | United States | 3.4% |
| 7 Gilead Sciences Inc | Health Care | United States | 3.3% |
| 8 Repsol SA | Energy | Spain | 3.2% |
| 9 Hess Corp | Energy | United States | 3.2% |
| 10 Aker BP ASA | Energy | Norway | 3.2% |


Contributors

| Top contributors | Rel. contribution | Worst contributors | Rel. contribution |
|--------------------------|-------------------|--------------------|-------------------|
| Colgate-Palmolive Co | 0.1% | Anglo American PLC | -0.9% |
| Estee Lauder Cos Inc/The | 0.0% | Dow Inc | -0.8% |
| AstraZeneca PLC | 0.0% | Aker BP ASA | -0.7% |
| Coca-Cola Co/The | 0.0% | NVIDIA Corp | -0.5% |
| Merck & Co Inc | 0.0% | Intel Corp | -0.5% |

Top sectors



Top currencies



Allocation

| | | | | | | |
|----------------------------|-------------|--------------|--------------|---------|-------|------|
| Top ten concentration | Top ten 35% | Rest 65% | | | | |
| Gender ratings (Bloomberg) | Top 50, 52% | Top 100, 12% | Top 500, 36% | | | |
| ESG ratings (MSCI) | AAA 28% | AA 42% | A 30% | | | |
| MSCI World ESG rtg. (MSCI) | AAA 13% | AA 24% | A 30% | BBB 21% | BB 9% | B 3% |